论文部分内容阅读
为了探讨SP化疗方案(替吉奥+顺铂)一线治疗晚期胃癌临床疗效及毒副反应,对经病理学确诊的19例晚期胃癌患者采用SP方案化疗:替吉奥(S-1)按体表面积分别每次40(<1.25m2)、50(1.25～1.5m2)和60mg(>1.5m2)早晚各口服1次,d1～d21;顺铂30mg/m2静脉滴入d7～d8;5周为1个周期,直至肿瘤进展或不良反应无法耐受,每2个周期评价疗效及毒副反应。19例均可评价疗效,CR 1例,PR 7例,SD 6例,PD 5例,总有效率(RR)为42.1%(8/19),疾病控制率(DCR)为73.7%(14/19)。中位疾病进展时间(TTP)5.8个月,中位总生存期11.3个月,1年生存率为47.3%。毒副反应主要为血液学毒性及胃肠道反应,手足综合征发生率为21.0%。初步研究结果提示,SP方案治疗晚期胃癌有较高的疾病控制率,患者耐受性良好,生活质量高,是较理想的晚期胃癌一线治疗方案。
In order to investigate the clinical efficacy and toxicity of SP chemotherapy regimen (TIGO + Cisplatin) in the first-line treatment of advanced gastric cancer, 19 patients with advanced gastric cancer diagnosed by pathology were treated with SP regimen chemotherapy (T-1) The surface area was dosed orally once a day for 40 (<1.25m2), 50 (1.25-1.5m2) and 60mg (> 1.5m2), d1 ~ d21 and 30mg / m2 for d7 ~ d8 respectively. 1 cycle, until the tumor progression or adverse reactions can not tolerate, evaluate the efficacy and toxicity every 2 cycles. All of the 19 patients were evaluated as CR 1, PR 7, SD 6, and PD 5 with a total effective rate (RR) of 42.1% (8/19) and a disease control rate (DCR) of 73.7% 19). The median time to progression (TTP) was 5.8 months, with a median overall survival of 11.3 months and a one-year survival of 47.3%. Toxic and side effects mainly hematological toxicity and gastrointestinal reactions, hand-foot syndrome was 21.0%. Preliminary results suggest that SP regimen in the treatment of advanced gastric cancer have a higher rate of disease control, patients with good tolerance, high quality of life, is an ideal first-line treatment of advanced gastric cancer.